The Administration Core is the central core of the Mayo Clinic SPORE in Ovarian Cancer. It will provide organizational support for the leadership of the SPORE, facilitate communication among the component activities of the SPORE, and provide an organizational portal for collaborations outside the SPORE. Specifically, the Administration Core will: 1) provide leadership, organizational support, and financial management for SPORE investigators;2) oversee formal procedures for systematic scientific review of SPORE research projects;3) oversee and coordinate the efforts of all cores to ensure that the research projects are supported effectively;4) monitor'accrual, including minority accrual, to all SPORE clinical trials and biospecimen collections;5) provide administrative support to the Developmental Research Program and Career Developmental Program;6) assure ongoing integration and participation of the Ovarian SPORE in the activities of the Mayo Clinic Cancer Center;7) facilitate activities of the Ovarian SPORE advocates; 8) serve as the administrative liaison between the Mayo Clinic SPORE and the NCI SPORE Program, other Mayo SPOREs, and external collaborators;and 9) communicate SPORE-related research developments among the Mayo Clinic SPORE investigators, to the scientific community at large, and to the public. Dr. Hartmann will direct the Administration Core, in close consultation with the SPORE Co-PI/Administration Core Co-Director, and Executive Committee, to maximize the effectiveness of the Ovarian SPORE effort and its clinical-translational impact.

Public Health Relevance

The Administration Core provides the organizational infrastructure necessary to perform the work proposed in this SPORE application.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA136393-05
Application #
8547768
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
5
Fiscal Year
2013
Total Cost
$138,222
Indirect Cost
$51,290
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Zhang, Qing; Wang, Chen; Cliby, William A (2018) Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer. Gynecol Oncol :
Morehead, Lauren C; Cannon, Martin J (2018) Further clinical advancement of dendritic cell vaccination against ovarian cancer. Ann Res Hosp 2:
Botuyan, Maria Victoria; Cui, Gaofeng; Drané, Pascal et al. (2018) Mechanism of 53BP1 activity regulation by RNA-binding TIRR and a designer protein. Nat Struct Mol Biol 25:591-600
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Earp, Madalene; Tyrer, Jonathan P; Winham, Stacey J et al. (2018) Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS One 13:e0197561
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wu, Chenming; Luo, Kuntian; Zhao, Fei et al. (2018) USP20 positively regulates tumorigenesis and chemoresistance through ?-catenin stabilization. Cell Death Differ 25:1855-1869
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Li, Lei; Liu, Tongzheng; Li, Yunhui et al. (2018) The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization. Oncogene 37:2422-2431

Showing the most recent 10 out of 294 publications